부산대학교 도서관

OBJECTIVE The objective of the study was to evaluate the outcomes of central neurocytoma treatments. METHODS Between 2003 and 2019, 23 post-operative patients with central neurocytoma were included in the study. According to the World Health Organization (WHO) 2021 classification, 14 patients were classified as atypical neurocytoma. Gross total resection was performed in 12 patients whereas subtotal resection (STR) was performed in ten patients and eight patients had residual disease. In total, 13 patients received radiotherapy (RT), nine of whom were irradiated postoperatively, and four patients were irradiated after relapse. Recurrence and progression-free survival (PFS) of each subgroup were presented. RESULTS The median follow-up was 59 months (15-262 months). The 5-year overall survival (OS) was 89.3% and PFS was 83.4%. During follow-up in total three patients died; two patients had disease progressionrelated death, and one patient died because of his comorbidities. Comparing the outcome of RT group and the observation group; there was no recurrence in the radiotherapy group, but three recurrences or progression were detected in the observation arm. There was no statistical significance (p=0.257) due to the low number of patients in this subgroup. Patients with extraventricular tumors received postoperative radiotherapy; however, patients had recurrences and died due to disease progression. Furthermore, there was no statistical significance (p=1.00) when the operation type was evaluated. In terms of histopathology, recurrence or progression was observed in two patients with typical CN and one patient with atypical histology, which was not statistically significant (p=0.247). CONCLUSION All treatment modalities were applied in our cohort, but due to the small number of patients, the significance of any modality could not be demonstrated. However, the prognosis of the patients with extraventricular pathology was very poor and two patients died due to the disease. [ABSTRACT FROM AUTHOR]